Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: firstname.lastname@example.org.Show MeSH
Related in: MedlinePlus
Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4).
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: email@example.com.